$OMER
OMEROS CORP

2019 Q4 Form 10-Q Financial Statement

#000155837019010806 Filed on November 12, 2019

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q3 2018 Q3
Revenue $33.42M $29.86M $4.608M
YoY Change 51.78% 547.92% -78.72%
Cost Of Revenue $400.0K $278.0K $36.00K
YoY Change 150.0% 672.22% -80.43%
Gross Profit $33.02M $29.58M $4.572M
YoY Change 51.05% 546.94% -78.71%
Gross Profit Margin 98.81% 99.07% 99.22%
Selling, General & Admin $16.13M $16.93M $13.15M
YoY Change 8.33% 28.75% 11.91%
% of Gross Profit 48.85% 57.24% 287.62%
Research & Development $40.59M $23.75M $26.86M
YoY Change 59.49% -11.6% 81.07%
% of Gross Profit 122.93% 80.28% 587.53%
Depreciation & Amortization $530.0K $430.0K $220.0K
YoY Change 70.97% 95.45% 46.67%
% of Gross Profit 1.61% 1.45% 4.81%
Operating Expenses $56.72M $23.75M $40.05M
YoY Change 40.08% -40.71% 49.62%
Operating Profit -$23.70M -$11.10M -$35.44M
YoY Change 28.31% -68.68% 593.58%
Interest Expense -$5.810M $5.715M $4.602M
YoY Change 12.82% 24.19% 65.54%
% of Operating Profit
Other Income/Expense, Net $290.0K $353.0K $572.0K
YoY Change 93.33% -38.29% 40.2%
Pretax Income -$29.23M -$16.46M -$39.47M
YoY Change -19.83% -58.29% 427.67%
Income Tax
% Of Pretax Income
Net Earnings -$29.23M -$16.46M -$39.47M
YoY Change 24.18% -58.29% 427.56%
Net Earnings / Revenue -87.46% -55.14% -856.6%
Basic Earnings Per Share
Diluted Earnings Per Share -$577.4K -$333.4K -$811.3K
COMMON SHARES
Basic Shares Outstanding 49.75M 49.29M 48.56M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q4 2019 Q3 2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $60.80M $27.30M $55.20M
YoY Change 0.5% -50.54% -36.41%
Cash & Equivalents $3.100M $8.900M $2.787M
Short-Term Investments $57.70M $18.50M $52.40M
Other Short-Term Assets $6.600M $5.400M $8.300M
YoY Change 1.54% -34.94% 45.61%
Inventory $1.147M $1.173M $214.0K
Prepaid Expenses $8.334M
Receivables $35.10M $29.80M $2.200M
Other Receivables $111.0K $122.0K $132.0K
Total Short-Term Assets $103.7M $63.80M $66.00M
YoY Change 15.44% -3.34% -44.02%
LONG-TERM ASSETS
Property, Plant & Equipment $3.829M $3.787M $2.520M
YoY Change -0.42% 50.28% 41.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.300M $2.400M $7.100M
YoY Change 4.55% -66.2% 22.41%
Total Long-Term Assets $33.22M $27.46M $9.609M
YoY Change 447.44% 185.82% 26.1%
TOTAL ASSETS
Total Short-Term Assets $103.7M $63.80M $66.00M
Total Long-Term Assets $33.22M $27.46M $9.609M
Total Assets $137.0M $91.26M $75.61M
YoY Change 42.77% 20.7% -39.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.328M $9.702M $8.847M
YoY Change -15.17% 9.66% 140.41%
Accrued Expenses $46.63M $34.00M $15.18M
YoY Change 54.47% 123.95% -25.08%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.200M $1.100M $560.0K
YoY Change 34.98% 96.43% 52.17%
Total Short-Term Liabilities $55.46M $46.75M $24.59M
YoY Change 48.46% 90.15% -0.42%
LONG-TERM LIABILITIES
Long-Term Debt $159.8M $157.2M $131.7M
YoY Change 6.11% 19.37% 59.09%
Other Long-Term Liabilities $30.80M $27.20M $8.300M
YoY Change 275.61% 227.71% -5.68%
Total Long-Term Liabilities $190.6M $184.4M $131.7M
YoY Change 20.03% 40.02% 59.09%
TOTAL LIABILITIES
Total Short-Term Liabilities $55.46M $46.75M $24.59M
Total Long-Term Liabilities $190.6M $184.4M $131.7M
Total Liabilities $246.0M $231.2M $156.3M
YoY Change 25.45% 47.94% 45.42%
SHAREHOLDERS EQUITY
Retained Earnings -$734.6M -$705.4M -$626.6M
YoY Change 13.0% 12.58% 23.63%
Common Stock $625.6M $565.5M $490.0K
YoY Change 13.75% 115302.24% 2.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$109.0M -$139.9M -$89.00M
YoY Change
Total Liabilities & Shareholders Equity $137.0M $91.26M $75.61M
YoY Change 42.77% 20.7% -39.76%

Cashflow Statement

Concept 2019 Q4 2019 Q3 2018 Q3
OPERATING ACTIVITIES
Net Income -$29.23M -$16.46M -$39.47M
YoY Change 24.18% -58.29% 427.56%
Depreciation, Depletion And Amortization $530.0K $430.0K $220.0K
YoY Change 70.97% 95.45% 46.67%
Cash From Operating Activities -$23.01M -$7.520M -$36.87M
YoY Change -6.69% -79.6% 229.2%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$40.00K -$80.00K
YoY Change -90.0% -50.0% 166.67%
Acquisitions
YoY Change
Other Investing Activities -$39.23M $9.380M $33.16M
YoY Change 1628.19% -71.71% -155.72%
Cash From Investing Activities -$39.24M $9.340M $33.06M
YoY Change 1562.71% -71.75% -155.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $54.20M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 56.48M 3.060M 3.710M
YoY Change 87.7% -17.52% -94.57%
NET CHANGE
Cash From Operating Activities -23.01M -7.520M -36.87M
Cash From Investing Activities -39.24M 9.340M 33.06M
Cash From Financing Activities 56.48M 3.060M 3.710M
Net Change In Cash -5.770M 4.880M -100.0K
YoY Change -287.95% -4980.0% -95.76%
FREE CASH FLOW
Cash From Operating Activities -$23.01M -$7.520M -$36.87M
Capital Expenditures -$10.00K -$40.00K -$80.00K
Free Cash Flow -$23.00M -$7.480M -$36.79M
YoY Change -6.35% -79.67% 229.36%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q3 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:PropertyPlantAndEquipmentNet
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001285819
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49525474
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49011684
dei Document Type
DocumentType
10-Q
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2019-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34475
dei Entity Registrant Name
EntityRegistrantName
OMEROS CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WA
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-1663741
dei Entity Address Address Line1
EntityAddressAddressLine1
201 Elliott Avenue West
dei Entity Address City Or Town
EntityAddressCityOrTown
Seattle
dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98119
dei City Area Code
CityAreaCode
206
dei Local Phone Number
LocalPhoneNumber
676-5000
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
OMER
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
49747818
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8861000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5861000
CY2019Q3 us-gaap Short Term Investments
ShortTermInvestments
18481000
CY2018Q4 us-gaap Short Term Investments
ShortTermInvestments
54637000
CY2019Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
29931000
CY2018Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
22818000
CY2019Q3 us-gaap Inventory Net
InventoryNet
1173000
CY2018Q4 us-gaap Inventory Net
InventoryNet
88000
CY2019Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5353000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6463000
CY2019Q3 us-gaap Assets Current
AssetsCurrent
63799000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
89867000
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3787000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3845000
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
21302000
CY2019Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1154000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1154000
CY2019Q3 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
1221000
CY2018Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
1070000
CY2019Q3 us-gaap Assets
Assets
91263000
CY2018Q4 us-gaap Assets
Assets
95936000
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
9702000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6281000
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33996000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30186000
CY2019Q3 omer Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
3055000
CY2018Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
889000
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
46753000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
37356000
CY2019Q3 omer Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
28654000
CY2018Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
1578000
CY2019Q3 us-gaap Senior Long Term Notes
SeniorLongTermNotes
155771000
CY2018Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
148981000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
8177000
CY2019Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2019Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49525474
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49011684
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
495000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
490000
CY2019Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
564976000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
549479000
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-705386000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-650125000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-139915000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-100156000
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
91263000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
95936000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
29856000
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4608000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
78389000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7852000
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
278000
CY2018Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
36000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
464000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
355000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23746000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26862000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
69108000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
64414000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16933000
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13152000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
48493000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
36830000
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
40957000
CY2018Q3 us-gaap Costs And Expenses
CostsAndExpenses
40050000
us-gaap Costs And Expenses
CostsAndExpenses
118065000
us-gaap Costs And Expenses
CostsAndExpenses
101599000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11101000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-35442000
us-gaap Operating Income Loss
OperatingIncomeLoss
-39676000
us-gaap Operating Income Loss
OperatingIncomeLoss
-93747000
CY2019Q3 us-gaap Interest Expense
InterestExpense
5715000
CY2018Q3 us-gaap Interest Expense
InterestExpense
4602000
us-gaap Interest Expense
InterestExpense
16846000
us-gaap Interest Expense
InterestExpense
11104000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
353000
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
572000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1261000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1628000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-16463000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-39472000
us-gaap Net Income Loss
NetIncomeLoss
-55261000
us-gaap Net Income Loss
NetIncomeLoss
-103223000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16463000
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39472000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-55261000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-103223000
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.33
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.81
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.12
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.13
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49373156
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
48647416
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49157055
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
48437870
us-gaap Profit Loss
ProfitLoss
-55261000
us-gaap Profit Loss
ProfitLoss
-103223000
us-gaap Share Based Compensation
ShareBasedCompensation
10468000
us-gaap Share Based Compensation
ShareBasedCompensation
8896000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
6790000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
4308000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1262000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
654000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
7113000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-14847000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1085000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-229000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-959000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2608000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
6921000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2183000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37059000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-79080000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
318000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
474000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
594000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
45514000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
36750000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
73500000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
35838000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
27512000
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
44550000
omer Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
5034000
omer Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
6720000
omer Increase Decrease In Restricted Investments
IncreaseDecreaseInRestrictedInvestments
-56000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
813000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
365000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4221000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
50961000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3000000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-607000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5861000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3394000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8861000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2787000
us-gaap Interest Paid Net
InterestPaidNet
6811000
us-gaap Interest Paid Net
InterestPaidNet
6796000
omer Noncash Transaction Conversion Of Accrued Interest Into Notes Payable
NoncashTransactionConversionOfAccruedInterestIntoNotesPayable
3246000
omer Warrants Issued
WarrantsIssued
1424000
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
886000
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
579000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 12.25pt;">Organization</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We are a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system, and immune-related diseases, including cancers. Our first drug product, OMIDRIA, is marketed in the United States (U.S.) for use during cataract surgery or intraocular lens replacement.</p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019Q3 omer Number Of Phase Three Programs
NumberOfPhaseThreePrograms
3
CY2018Q4 omer Program Reinstatement Period
ProgramReinstatementPeriod
P2Y
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 12.25pt;">Use of Estimates</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant items subject to such estimates include revenue recognition, stock-based compensation expense and accruals for clinical trials, manufacturing of drug product and clinical drug supply and contingencies. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; however, actual results could differ from these estimates.</p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11737837
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11737837
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10366645
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10366645
CY2019Q3 us-gaap Accounts Receivable Net
AccountsReceivableNet
29809000
CY2018Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
22654000
CY2019Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
122000
CY2018Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
164000
CY2019Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
29931000
CY2018Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
22818000
CY2019Q3 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
1500000
CY2018Q4 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
400000
CY2019Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
43000
CY2018Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
83000
CY2019Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
379000
CY2019Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
751000
CY2018Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5000
CY2019Q3 us-gaap Inventory Net
InventoryNet
1173000
CY2018Q4 us-gaap Inventory Net
InventoryNet
88000
omer Number Of Option To Extend
NumberOfOptionToExtend
2
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
true
CY2019Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P5Y
CY2019Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9294000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8090000
CY2019Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5507000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4245000
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3787000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3845000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1300000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
700000
CY2019Q3 omer Accrued Contract Research Costs
AccruedContractResearchCosts
10559000
CY2018Q4 omer Accrued Contract Research Costs
AccruedContractResearchCosts
12012000
CY2019Q3 omer Accrued Sales Rebates Fees And Discounts Current
AccruedSalesRebatesFeesAndDiscountsCurrent
9691000
CY2018Q4 omer Accrued Sales Rebates Fees And Discounts Current
AccruedSalesRebatesFeesAndDiscountsCurrent
8075000
CY2019Q3 us-gaap Interest Payable Current
InterestPayableCurrent
4922000
CY2018Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1677000
CY2019Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3371000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2714000
CY2019Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3162000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3669000
CY2019Q3 omer Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
1432000
CY2018Q4 omer Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
820000
CY2019Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
859000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1219000
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33996000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30186000
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8900000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5900000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0
CY2018 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0
CY2019Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.1226
CY2018Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
687000
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
21302000
CY2019Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
2774000
CY2019Q3 omer Lease Right Of Use Asset
LeaseRightOfUseAsset
24076000
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1927000
CY2019Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1128000
CY2019Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
27242000
CY2019Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1412000
CY2019Q3 omer Lease Liability
LeaseLiability
31709000
CY2019Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y1M6D
CY2019Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M24D
CY2019Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1285
us-gaap Operating Lease Cost
OperatingLeaseCost
3121000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
984000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
248000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
275000
us-gaap Variable Lease Cost
VariableLeaseCost
1424000
us-gaap Sublease Income
SubleaseIncome
673000
us-gaap Lease Cost
LeaseCost
5379000
us-gaap Operating Lease Payments
OperatingLeasePayments
4962000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
248000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
813000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1358000
CY2019Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
342000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5755000
CY2019Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
1248000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5826000
CY2019Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
18742000
CY2019Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
330000
CY2019Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
889000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5898000
CY2019Q3 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
296000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
5972000
CY2019Q3 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
95000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
23102000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
47911000
CY2019Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
2870000
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
29169000
CY2019Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
2540000
CY2019Q3 omer Long Term Purchase Commitment Termination Fee
LongTermPurchaseCommitmentTerminationFee
22600000
omer Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
5000000.0
omer Stock Issued During Period Shares Stock Options And Warrants Exercised
StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised
513790
omer Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
6700000
omer Stock Issued During Period Shares Stock Options And Warrants Exercised
StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised
763575
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-100156000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
108000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3374000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-24345000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-121019000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1600000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3598000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-14453000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-130274000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3326000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3496000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-16463000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-139915000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-2814000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2966000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-30054000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
-29215000
CY2018Q2 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
1424000
CY2018Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2190000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3000000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-33697000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
-56298000
CY2018Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3844000
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2929000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-39472000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
-88997000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3496000
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2929000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10468000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8896000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10313138
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.22
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1956205
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
14.17
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
513790
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
9.80
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
260831
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
16.07
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11494722
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.67
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y3M
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
56610000
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
11126906
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
11.59
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y2M1D
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
55668000
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
8117842
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.68
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y2M12D
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
47725000

Files In Submission

Name View Source Status
0001558370-19-010806-index-headers.html Edgar Link pending
0001558370-19-010806-index.html Edgar Link pending
0001558370-19-010806.txt Edgar Link pending
0001558370-19-010806-xbrl.zip Edgar Link pending
ex-10d1.htm Edgar Link pending
ex-10d1g001.jpg Edgar Link pending
ex-31d1.htm Edgar Link pending
ex-31d2.htm Edgar Link pending
ex-32d1.htm Edgar Link pending
ex-32d2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
omer-20190930.xsd Edgar Link pending
omer-20190930x10q942bc6.htm Edgar Link pending
omer-20190930x10q942bc6006.jpg Edgar Link pending
omer-20190930x10q942bc6_htm.xml Edgar Link completed
omer-20190930_cal.xml Edgar Link unprocessable
omer-20190930_def.xml Edgar Link unprocessable
omer-20190930_lab.xml Edgar Link unprocessable
omer-20190930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending